NCT02978599View on ClinicalTrials.gov

Clinical Trial of AVL-3288 in Schizophrenia Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 26, 2018

Study Completion Date

November 2, 2018

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

AVL-3288

daily for 5 days

DRUG

Placebo

daily for 5 days

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02978599 - Clinical Trial of AVL-3288 in Schizophrenia Patients | Biotech Hunter | Biotech Hunter